CytRx Corporation Initiates Pharmacokinetic Clinical Trial with Bafetinib in Brain Cancer

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq:CYTR) a biopharmaceutical company specializing in oncology, today announced initiation of a pharmacokinetic clinical trial with its oncology drug candidate bafetinib in patients with recurrent brain tumors. Results from this trial are expected in the second quarter of 2011 and will be used in evaluating potential further clinical development of bafetinib in patients with brain cancer.
MORE ON THIS TOPIC